Hybrid Closed-Loop System in LADA Patients: A Randomized Trial

Inclusion Criteria: 1. Age between 18 and 70 years old. 2. Meet the diagnostic criteria for LADA in the "Chinese Expert Consensus on the Diagnosis and Treatment of Latent Autoimmune Diabetes in Adults (2021 Edition)": * The onset age of diabetes is ≥ 18 years old. * Positive for islet autoantibodies or islet autoimmunity T cells. * Do not rely on insulin therapy for at least 6 months after the diagnosis of diabetes. 3. Patients are able to correctly use insulin pumps and CGM devices and have a certain learning ability and operational ability. 4. Baseline HbA1c \> 7.0% or HbA1c \> 6.0% combined with hypoglycemia. 5. Patients agree to participate in the study and sign the informed consent form. Exclusion Criteria: 1. The patient has been clearly diagnosed with type 2 diabetes or special types of diabetes. 2. The patient has experienced acute diabetic complications within the past 1 month, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc. 3. The patient has severe symptoms of hypoglycemia intolerance. 4. The patient has skin diseases such as rashes and prurigo, or abnormal coagulation function. 5. The patient has diseases related to impaired glucose metabolism, such as uncontrolled hyperthyroidism, hypothyroidism, Cushing's syndrome, etc. 6. The patient has comorbid severe liver, kidney, gastrointestinal, hematological, brain, circulatory system diseases, etc. 7. The patient has other severe chronic diseases (such as malignant tumors, end-stage organ failure, etc.). 8. The patient has impaired consciousness or mental illness, lacks self-control, and cannot express clearly. 9. Lactating women, pregnant women, or women who plan to become pregnant during the trial period. 10. The patient is currently using or has used glucocorticoids or other drugs that interfere with glucose metabolism within 1 month before screening. 11. The patient is allergic to the drugs involved in the clinical diagnosis and treatment plan. 12. The patient is currently using other closed-loop systems. 13. People who are not suitable for conventional insulin pump treatment and those with contraindications. 14. The patient is known or suspected to have an insulin-allergic constitution and is allergic to adhesive tape, insulin pumps, or CGM devices. Other situations where the researcher deems the patient unfit to participate in the clinical trial.